[{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"CANADA","productType":"Small molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CS12192","moa":"JAK3\/JAK1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PN-1007","moa":"MAG IgM","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Polyneuron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CD45-ADC","moa":"CD45","graph1":"Immunology","graph2":"IND Enabling","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Magenta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FCR001","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Talaris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","upfrontCash":"$25.0 million","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Tivozanib","moa":"VEGF","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0.42999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.42999999999999999,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lentivirus-Hematopoietic Stem Cell","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Expression Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Expression Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Expression Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Circuit Clinical","sponsor":"Intrommune Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"INT301","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Circuit Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Circuit Clinical \/ Intrommune Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Circuit Clinical \/ Intrommune Therapeutics"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IMP761","moa":"LAG-3","graph1":"Immunology","graph2":"IND Enabling","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Financing","leadProduct":"VRDN-001","moa":"IGF-1R","graph1":"Immunology","graph2":"IND Enabling","graph3":"Miragen Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Injection","sponsorNew":"Miragen Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"5","companyTruncated":"Miragen Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IN-001","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"5","companyTruncated":"Insignis Therapeutics \/ HLK Pharmacin"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sitaxentan","moa":"Endothelin Receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"T19","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Not Applicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"AGMB-101","moa":"MET","graph1":"Immunology","graph2":"IND Enabling","graph3":"AgomAb Therapeutics N.V","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"AgomAb Therapeutics N.V \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"AgomAb Therapeutics N.V \/ Redmile Group"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Targeted Pharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ARDS-003","moa":"CB2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetra BioPharma \/ Targeted Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Tetra BioPharma \/ Targeted Pharmaceuticals"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"SLN501","moa":"Complement C3","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":2.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":2.02,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Mallinckrodt","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt"},{"orgOrder":0,"company":"Triastek","sponsor":"Matrix Partners China","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Series B Financing","leadProduct":"T19","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Delayed-release Tablet","sponsorNew":"Triastek \/ Matrix Partners China","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Matrix Partners China"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"SBT-77-7101","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sonoma Biotherapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sonoma Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Thunderbolt","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$0.7 million","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"AUR200","moa":"B-Cell activating factor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Thunderbolt","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Thunderbolt \/ Aurinia","highestDevelopmentStatusID":"5","companyTruncated":"Thunderbolt \/ Aurinia"},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$6.0 million","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"AUR300","moa":"M2 macrophages dysregulation","graph1":"Immunology","graph2":"IND Enabling","graph3":"Riptide Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Riptide Bioscience \/ Aurinia","highestDevelopmentStatusID":"5","companyTruncated":"Riptide Bioscience \/ Aurinia"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Immunology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"3H Health Investment","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"AP-302","moa":"MASP-2","graph1":"Immunology","graph2":"IND Enabling","graph3":"Alebund Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Alebund Pharmaceuticals \/ 3H Health Investment","highestDevelopmentStatusID":"5","companyTruncated":"Alebund Pharmaceuticals \/ 3H Health Investment"},{"orgOrder":0,"company":"Cryostem","sponsor":"Rheos Medicines","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cryostem","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cryostem \/ Rheos","highestDevelopmentStatusID":"5","companyTruncated":"Cryostem \/ Rheos"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Multi-modular Engineered Treg Cell Therapy","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"QEL-001","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0.16,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Quell Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Almirall","pharmaFlowCategory":"D","upfrontCash":"$23.6 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"ISB 880","moa":"IL-1RAP","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ichnos Sciences \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Ichnos Sciences \/ Almirall"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Kyverna Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Northpond Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Kyverna Therapeutics \/ Northpond Ventures"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MuSK-CAART","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Not Applicable"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Vaccine","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"VLP Peanut","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Allergy Therapeutics \/ AGC Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Allergy Therapeutics \/ AGC Biologics"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"SLN501","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":2.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":2.02,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Mallinckrodt","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mescaline","moa":"5-HT2A receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Biomind Labs \/ Not Applicable"},{"orgOrder":0,"company":"ValenzaBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonigutamab","moa":"IGF-1R","graph1":"Immunology","graph2":"IND Enabling","graph3":"ValenzaBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"ValenzaBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ValenzaBio \/ Not Applicable"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Allergy Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Vaccine","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"VLP-Based Peanut Allergy Vaccine","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AGC Biologics \/ Allergy Therapeutic","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Allergy Therapeutic"},{"orgOrder":0,"company":"Delta Crystallon","sponsor":"Serenity Bioworks","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Large molecule","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Recombinant Human HspB5","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Delta Crystallon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Delta Crystallon \/ Serenity Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Delta Crystallon \/ Serenity Bioworks"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"IGF-1R","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Zenas BioPharma \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioPharma \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymoangioblast-derived Mesenchymal Stem Cells","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cynata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"TNF alpha","graph1":"Immunology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IMP761","moa":"LAG-3","graph1":"Immunology","graph2":"IND Enabling","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT 1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"IGF-1R","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Zenas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"HCW9302","moa":"Tregs","graph1":"Immunology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"DWP213388","moa":"ITK\/BTK","graph1":"Immunology","graph2":"IND Enabling","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Daewoong Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"STP144G","moa":"Complement factor B","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMP761","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Avenanthramide","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ceapro \/ Not Applicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IMG-008","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inmagene Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"NX\u20110479","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Vitalli Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"VIT-801","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vitalli Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Vitalli Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vitalli Bio \/ Not Applicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CABA-201","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"VYN202","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"DT-001","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Dualyx","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Dualyx \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"5","companyTruncated":"Dualyx \/ Fountain Healthcare Partners"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"CABA-201","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ TD Cowen"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"CABA-201","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ TD Cowen"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Imvotamab","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IGM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"IASO-782","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Not Applicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-KIT","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"RPT-2950","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rome Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Rome Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Rome Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-KIT","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"AnaptysBio","pharmaFlowCategory":"D","upfrontCash":"$10.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CBS004","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ AnaptysBio","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ AnaptysBio"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-KIT","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CABA-201","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Not Applicable"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Bessemer Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Series B Financing","leadProduct":"S-1117","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"Seismic Therapeutic \/ Bessemer Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Therapeutic \/ Bessemer Venture Partners"},{"orgOrder":0,"company":"Vandria","sponsor":"Eurostars","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Financing","leadProduct":"VNA-052","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Vandria \/ Eurostars","highestDevelopmentStatusID":"5","companyTruncated":"Vandria \/ Eurostars"},{"orgOrder":0,"company":"GenBio","sponsor":"Strainsforpains","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"GenBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"GenBio \/ Strainsforpains","highestDevelopmentStatusID":"5","companyTruncated":"GenBio \/ Strainsforpains"},{"orgOrder":0,"company":"Synthekine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"STK-009","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Synthekine \/ Not Applicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"MB-106","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"TRX103","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Tr1X Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Tr1X Bio \/ The Column Group","highestDevelopmentStatusID":"5","companyTruncated":"Tr1X Bio \/ The Column Group"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ALLO-329","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ATA3219","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LP-410","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CNTY-101","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Century Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Scleroderma Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Amlitelimab","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Scleroderma Research Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scleroderma Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Scleroderma Research Foundation \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Not Applicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CLN-978","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"CLN-978","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"Alivexis","sponsor":"Melodia Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"MDI-0151","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Alivexis","amount2":0.28000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Alivexis \/ Melodia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Alivexis \/ Melodia Therapeutics"},{"orgOrder":0,"company":"JJP Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"JJP-1212","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"JJP Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"JJP Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"JJP Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"5","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
